glaucomaНациональный журнал ГлаукомаNational Journal glaucoma2078-41042311-6862Federal State Budgetary Institution of Science “Krasnov Research Institute of Eye Diseases”10.25700/NJG.2020.02.07glaucoma-298Research ArticleОБЗОР ЛИТЕРАТУРЫREVIEW OF LITERATUREКлиническая оценка фиксированной комбинации аналогов простагландинов и бета-адреноблокаторовClinical evaluation of a fixed combination of prostaglandin analogues and beta-blockersЕричевВ. П.ErichevV. P.

Еричев Валерий Петрович, доктор медицинских наук, профессор, руководитель отдела глаукомы

119021, Москва, ул. Россолимо, 11А

 

Med.Sc.D., Professor, Head of Glaucoma Department

11A Rossolimo st., Moscow, 119021

erichev@reic.ruВитковА. А.VitkovA. A.

Ординатор

119021, Москва, ул. Россолимо, 11А

Resident

11A Rossolimo st., Moscow, 119021

ФГБНУ «НИИ глазных болезней»РоссияScientific Research Institute of Eye DiseasesRussian Federation2020101020201925965Copyright © Еричев В.П., Витков А.А., 20202020Еричев В.П., Витков А.А.Erichev V.P., Vitkov A.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.glaucomajournal.ru/jour/article/view/298

В настоящее время основным методом лечения глаукомы является гипотензивная терапия. Зачастую достижение целевого уровня офтальмотонуса возможно лишь при одновременном применении нескольких топических гипотензивных средств. Сложный режим инстилляций и высокая частота нежелательных явлений способствуют уменьшению приверженности лечению. Все это приводит к снижению эффективности проводимой терапии и прогрессированию заболевания. Применение фиксированных комбинаций препаратов позволяет упростить режим закапываний в течение суток и снизить частоту развития нежелательных явлений. Применение фиксированных комбинаций аналогов простагландинов и тимолола малеата позволяет достигать более выраженного гипотензивного эффекта при однократной инстилляции препарата в течение суток. В данном обзоре мы попробуем обобщить современные данные о фиксированной комбинации латанопроста и тимолола малеата, ее фармакологических свойствах и гипотензивном эффекте в сравнении с другими гипотензивными средствами и их комбинациями.

Currently, topical hypotensive therapy is the main means of glaucoma treatment. Frequently, the achievement of the target level of ocular pressure is possible only with the simultaneous use of several topical hypotensive drugs. A complex instillation regimen and a high incidence of adverse effects contribute to compliance reduction. All this leads to therapy efficacy decrease and the disease progression. The use of fixed combinations can simplify the instillation regimen during the day and reduce the incidence of adverse effects. The use of fixed combinations of prostaglandin analogues and timolol maleate allows us to achieve a more pronounced hypotensive effect with a single instillation of the drug during the day. In this review, we will try to summarize current data on the fixed combination of latanoprost and timolol maleate (FCLT), its pharmacological effects and hypotensive effectiveness, compared to other antihypertensive drugs and their combinations.

фиксированная комбинациялатанопрост и тимололвнутриглазное давлениенежелательные явленияfixed combinationlatanoprost and timololintraocular pressureadverse effectsReferencesTham Y.C., Li X., Wong T.Y., Quigley H.A., Aung T., Cheng C.Y. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology. 2014; 121(11):2081-2090. doi:10.1016/j.ophtha.2014.05.013Tham Y.C., Li X., Wong T.Y., Quigley H.A., Aung T., Cheng C.Y. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology. 2014; 121(11):2081-2090. doi:10.1016/j.ophtha.2014.05.013Kapetanakis V.V., Chan M.P., Foster P.J., Cook D.G., Owen C.G., Rudnicka A.R. Global variations and time trends in the prevalence of primary open angle glaucoma (POAG): a systematic review and meta-analysis. Br J Ophthalmol. 2016; 100(1):86-93. doi:10.1136/bjophthalmol-2015-307223Kapetanakis V.V., Chan M.P., Foster P.J., Cook D.G., Owen C.G., Rudnicka A.R. Global variations and time trends in the prevalence of primary open angle glaucoma (POAG): a systematic review and meta-analysis. Br J Ophthalmol. 2016; 100(1):86-93. doi:10.1136/bjophthalmol-2015-307223Kass M.A., Heuer D.K., Higginbotham E.J., Johnson C.A., Keltner J.L., Miller J.P. et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Oph- thalmol. 2002; 120(6):701-713; discussion 829-730. doi:10.1001/archopht.120.6.701Kass M.A., Heuer D.K., Higginbotham E.J., Johnson C.A., Keltner J.L., Miller J.P. et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Oph- thalmol. 2002; 120(6):701-713; discussion 829-730. doi:10.1001/archopht.120.6.701Leske M.C., Heijl A., Hyman L., Bengtsson B., Dong L., Yang Z. et al. Predictors of long-term progression in the early manifest glaucoma trial. Ophthalmology. 2007; 114(11):1965-1972. doi:10.1016/j.oph-tha.2007.03.016Leske M.C., Heijl A., Hyman L., Bengtsson B., Dong L., Yang Z. et al. Predictors of long-term progression in the early manifest glaucoma trial. Ophthalmology. 2007; 114(11):1965-1972. doi:10.1016/j.oph-tha.2007.03.016Алексеев В.Н., Малеванная О.А., Хаж Н.С. Причины низкой при- верженности к лечению больных первичной открытоугольной глаукомой. Офтальмологические ведомости. 2010; 3(4).Alekseev V.N., Malevannaya O.A., Haj N.S. The reasons of low adherence in primary open-angle glaucoma patients treatment. Ophtalmologicheskie vedomosti. 2010; 3(4). (In Russ.).Dunker S., Schmucker A., Maier H., Latanoprost/Timolol Fixed Com- bination Study G. Tolerability, quality of life, and persistency of use in patients with glaucoma who are switched to the fixed combination of latanoprost and timolol. Adv Ther. 2007; 24(2):376-386.Dunker S., Schmucker A., Maier H., Latanoprost/Timolol Fixed Com- bination Study G. Tolerability, quality of life, and persistency of use in patients with glaucoma who are switched to the fixed combination of latanoprost and timolol. Adv Ther. 2007; 24(2):376-386.Ocklind A. Effect of latanoprost on the extracellular matrix of the cili- ary muscle. A study on cultured cells and tissue sections. Exp Eye Res. 1998; 67(2):179-191. doi:10.1006/exer.1998.0508Ocklind A. Effect of latanoprost on the extracellular matrix of the cili- ary muscle. A study on cultured cells and tissue sections. Exp Eye Res. 1998; 67(2):179-191. doi:10.1006/exer.1998.0508Toris C.B., Gabelt B.T., Kaufman P.L. Update on the mechanism of action of topical prostaglandins for intraocular pressure reduction. Surv Ophthalmol. 2008; 53 Suppl1:S107-120. doi:10.1016/j.survoph-thal.2008.08.010Toris C.B., Gabelt B.T., Kaufman P.L. Update on the mechanism of action of topical prostaglandins for intraocular pressure reduction. Surv Ophthalmol. 2008; 53 Suppl1:S107-120. doi:10.1016/j.survoph-thal.2008.08.010Ichhpujani P., Katz L.J., Hollo G., Shields C.L., Shields J.A., Marr B. et al. Comparison of human ocular distribution of bimatoprost and latanoprost. J Ocul Pharmacol Ther. 2012; 28(2):134-145. doi:10.1089/jop.2011.0097Ichhpujani P., Katz L.J., Hollo G., Shields C.L., Shields J.A., Marr B. et al. Comparison of human ocular distribution of bimatoprost and latanoprost. J Ocul Pharmacol Ther. 2012; 28(2):134-145. doi:10.1089/jop.2011.0097Alm A., Stjernschantz J. Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning. A comparison with timolol. Scandinavian Latanoprost Study Group. Ophthalmology. 1995; 102(12):1743-1752. doi:10.1016/s0161-6420(95)30798-1Alm A., Stjernschantz J. Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning. A comparison with timolol. Scandinavian Latanoprost Study Group. Ophthalmology. 1995; 102(12):1743-1752. doi:10.1016/s0161-6420(95)30798-1Bartels S.P., Roth H.O., Jumblatt M.M., Neufeld A.H. Pharmacological effects of topical timolol in the rabbit eye. Invest Ophthalmol Vis Sci. 1980; 19(10):1189-1197.Bartels S.P., Roth H.O., Jumblatt M.M., Neufeld A.H. Pharmacological effects of topical timolol in the rabbit eye. Invest Ophthalmol Vis Sci. 1980; 19(10):1189-1197.Amyot M., Blondeau P. [Timolol maleate. Pharmacology and review of the literature]. Can J Ophthalmol. 1979; 14(3):208-214.Amyot M., Blondeau P. [Timolol maleate. Pharmacology and review of the literature]. Can J Ophthalmol. 1979; 14(3):208-214.Calissendorff B., Sjoquist B., Hogberg G., Grunge-Lowerud A. Bio- availability in the human eye of a fixed combination of latanoprost and timolol compared to monotherapy. J Ocul Pharmacol Ther. 2002; 18(2):127-131. doi:10.1089/108076802317373888Calissendorff B., Sjoquist B., Hogberg G., Grunge-Lowerud A. Bio- availability in the human eye of a fixed combination of latanoprost and timolol compared to monotherapy. J Ocul Pharmacol Ther. 2002; 18(2):127-131. doi:10.1089/108076802317373888Igarashi R., Togano T., Sakaue Y., Yoshino T., Ueda J., Fukuchi T. Effect on intraocular pressure of switching from latanoprost and travoprost monotherapy to timolol fixed combinations in patients with normal-tension glaucoma. J Ophthalmol. 2014; 2014:720385. doi:10.1155/2014/720385Igarashi R., Togano T., Sakaue Y., Yoshino T., Ueda J., Fukuchi T. Effect on intraocular pressure of switching from latanoprost and travoprost monotherapy to timolol fixed combinations in patients with normal-tension glaucoma. J Ophthalmol. 2014; 2014:720385. doi:10.1155/2014/720385Aptel F., Cucherat M., Denis P. Efficacy and tolerability of prostaglan- din-timolol fixed combinations: a meta-analysis of randomized clinical trials. Eur J Ophthalmol. 2012; 22(1):5-18. doi:10.5301/ejo.5000009Aptel F., Cucherat M., Denis P. Efficacy and tolerability of prostaglan- din-timolol fixed combinations: a meta-analysis of randomized clinical trials. Eur J Ophthalmol. 2012; 22(1):5-18. doi:10.5301/ejo.5000009Liu A.W., Gan L.Y., Yao X., Zhou J. Long-term assessment of pros- taglandin analogs and timolol fixed combinations vs prostaglan- din analogs monotherapy. Int J Ophthalmol. 2016; 9(5):750-756. doi:10.18240/ijo.2016.05.21Liu A.W., Gan L.Y., Yao X., Zhou J. Long-term assessment of pros- taglandin analogs and timolol fixed combinations vs prostaglan- din analogs monotherapy. Int J Ophthalmol. 2016; 9(5):750-756. doi:10.18240/ijo.2016.05.21Pfeiffer N., European Latanoprost Fixed Combination Study G. A com- parison of the fixed combination of latanoprost and timolol with its individual components. Graefes Arch Clin Exp Ophthalmol. 2002; 240(11):893-899. doi:10.1007/s00417-002-0553-0Pfeiffer N., European Latanoprost Fixed Combination Study G. A com- parison of the fixed combination of latanoprost and timolol with its individual components. Graefes Arch Clin Exp Ophthalmol. 2002; 240(11):893-899. doi:10.1007/s00417-002-0553-0Magacho L., Reis R., Shetty R.K., Santos L.C., Avila M.P. Efficacy of latano- prost or fixed-combination latanoprost-timolol in patients switched from a combination of timolol and a nonprostaglandin medication. Ophthal- mology. 2006; 113(3):442-445. doi:10.1016/j.ophtha.2005.11.011Magacho L., Reis R., Shetty R.K., Santos L.C., Avila M.P. Efficacy of latano- prost or fixed-combination latanoprost-timolol in patients switched from a combination of timolol and a nonprostaglandin medication. Ophthal- mology. 2006; 113(3):442-445. doi:10.1016/j.ophtha.2005.11.011Maruyama Y., Ikeda Y., Mori K., Ueno M., Yoshikawa H., Kinoshita S. Comparison between bimatoprost and latanoprost-timolol fixed combi- nation for efficacy and safety after switching patients from latanoprost. Clin Ophthalmol. 2015; 9:1429-1436. doi:10.2147/OPTH.S87613Maruyama Y., Ikeda Y., Mori K., Ueno M., Yoshikawa H., Kinoshita S. Comparison between bimatoprost and latanoprost-timolol fixed combi- nation for efficacy and safety after switching patients from latanoprost. Clin Ophthalmol. 2015; 9:1429-1436. doi:10.2147/OPTH.S87613Mesci C., Aydin N., Erbil H.H. Twenty-four-hour intraocular pres- sure control with latanoprost-timolol-fixed combination versus bima- toprost in patients who switched from timolol. J Glaucoma. 2011; 20(8):477-481. doi:10.1097/IJG.0b013e3181f7b180Mesci C., Aydin N., Erbil H.H. Twenty-four-hour intraocular pres- sure control with latanoprost-timolol-fixed combination versus bima- toprost in patients who switched from timolol. J Glaucoma. 2011; 20(8):477-481. doi:10.1097/IJG.0b013e3181f7b180Rossetti L., Sacchi M., Karabatsas C.H., Topouzis F., Vetrugno M., Cen- tofanti M. et al. Comparison of the effects of bimatoprost and a fixed combination of latanoprost and timolol on 24-hour blood and ocular perfusion pressures: the results of a randomized trial. BMC Ophthal- mol. 2015; 15:7. doi:10.1186/1471-2415-15-7Rossetti L., Sacchi M., Karabatsas C.H., Topouzis F., Vetrugno M., Cen- tofanti M. et al. Comparison of the effects of bimatoprost and a fixed combination of latanoprost and timolol on 24-hour blood and ocular perfusion pressures: the results of a randomized trial. BMC Ophthal- mol. 2015; 15:7. doi:10.1186/1471-2415-15-7Konstas A.G., Boboridis K., Tzetzi D., Kallinderis K., Jenkins J.N., Stewart W.C. Twenty-four-hour control with latanoprost-timolol-fixed combination therapy vs latanoprost therapy. Arch Ophthalmol. 2005; 123(7):898-902. doi:10.1001/archopht.123.7.898Konstas A.G., Boboridis K., Tzetzi D., Kallinderis K., Jenkins J.N., Stewart W.C. Twenty-four-hour control with latanoprost-timolol-fixed combination therapy vs latanoprost therapy. Arch Ophthalmol. 2005; 123(7):898-902. doi:10.1001/archopht.123.7.898Нестеров А.П., Алексеев В.Н., Алексеев И.Б., Амиров А.Н., Аста- хов Ю.С., Балалин С.В. Национальное руководство по глаукоме для практикующих врачей. Под ред. Е.А. Егорова, Ю.С. Астахова, В.П. Еричева. М.: ГЭОТАР-Медиа; 2015. 457 с.Nesterov A.P., Alekseev V.N., Alekseev I.B., Amirov A.N., Astakhov Yu.S., Balalin S.V. Natsional’noe rukovodstvo po glaukome: dlya praktikuyushchikh vrachei [National guidance for glaucoma: for medical practitioners]. Moscow: GEOTAR-Media Publ.; 2015. 457 p. (In Russ.).Claxton A.J., Cramer J., Pierce C. A systematic review of the associa- tions between dose regimens and medication compliance. Clin Ther. 2001; 23(8):1296-1310. doi:10.1016/s0149-2918(01)80109-0Claxton A.J., Cramer J., Pierce C. A systematic review of the associa- tions between dose regimens and medication compliance. Clin Ther. 2001; 23(8):1296-1310. doi:10.1016/s0149-2918(01)80109-0Xing Y., Jiang F.G., Li T. Fixed combination of latanoprost and timolol vs the individual components for primary open-angle glaucoma and ocular hypertension: a systematic review and meta-analysis. Int J Ophthalmol. 2014; 7(5):879-890. doi:10.3980/j.issn.2222-3959.2014.05.Xing Y., Jiang F.G., Li T. Fixed combination of latanoprost and timolol vs the individual components for primary open-angle glaucoma and ocular hypertension: a systematic review and meta-analysis. Int J Ophthalmol. 2014; 7(5):879-890. doi:10.3980/j.issn.2222-3959.2014.05.2626. Quaranta L., Biagioli E., Riva I., Rulli E., Poli D., Katsanos A. et al. Prosta- glandin analogs and timolol-fixed versus unfixed combinations or mono- therapy for open-angle glaucoma: a systematic review and meta-analysis. J Ocul Pharmacol Ther. 2013; 29(4):382-389. doi:10.1089/jop.2012.0186Quaranta L., Biagioli E., Riva I., Rulli E., Poli D., Katsanos A. et al. Prosta- glandin analogs and timolol-fixed versus unfixed combinations or mono- therapy for open-angle glaucoma: a systematic review and meta-analysis. J Ocul Pharmacol Ther. 2013; 29(4):382-389. doi:10.1089/jop.2012.0186Diestelhorst M., Larsson L.I., European-Canadian Latanoprost Fixed Combination Study G. A 12-week, randomized, double-masked, mul- ticenter study of the fixed combination of latanoprost and timolol in the evening versus the individual components. Ophthalmology. 2006; 113(1):70-76. doi:10.1016/j.ophtha.2005.06.027Diestelhorst M., Larsson L.I., European-Canadian Latanoprost Fixed Combination Study G. A 12-week, randomized, double-masked, mul- ticenter study of the fixed combination of latanoprost and timolol in the evening versus the individual components. Ophthalmology. 2006; 113(1):70-76. doi:10.1016/j.ophtha.2005.06.027Inoue K., Okayama R., Higa R., Wakakura M., Tomita G. Assess- ment of ocular hypotensive effect and safety 12 months after chang- ing from an unfixed combination to a latanoprost 0.005% + timolol maleate 0.5% fixed combination. Clin Ophthalmol. 2012; 6:607-612. doi:10.2147/OPTH.S30611Inoue K., Okayama R., Higa R., Wakakura M., Tomita G. Assess- ment of ocular hypotensive effect and safety 12 months after chang- ing from an unfixed combination to a latanoprost 0.005% + timolol maleate 0.5% fixed combination. Clin Ophthalmol. 2012; 6:607-612. doi:10.2147/OPTH.S30611Inoue K., Okayama R., Higa R., Tomita G. Efficacy and safety of switching to latanoprost 0.005%-timolol maleate 0.5% fixed-combination eyedrops from an unfixed combination for 36 months. Clin Ophthalmol. 2014; 8:1275-1279. doi:10.2147/OPTH.S63590Inoue K., Okayama R., Higa R., Tomita G. Efficacy and safety of switching to latanoprost 0.005%-timolol maleate 0.5% fixed-combination eyedrops from an unfixed combination for 36 months. Clin Ophthalmol. 2014; 8:1275-1279. doi:10.2147/OPTH.S63590Zhao J.L., Ge J., Li X.X., Li Y.M., Sheng Y.H., Sun N.X. et al. Com- parative efficacy and safety of the fixed versus unfixed combina- tion of latanoprost and timolol in Chinese patients with open-angle glaucoma or ocular hypertension. BMC Ophthalmol. 2011; 11:23. doi:10.1186/1471-2415-11-23Zhao J.L., Ge J., Li X.X., Li Y.M., Sheng Y.H., Sun N.X. et al. Com- parative efficacy and safety of the fixed versus unfixed combina- tion of latanoprost and timolol in Chinese patients with open-angle glaucoma or ocular hypertension. BMC Ophthalmol. 2011; 11:23. doi:10.1186/1471-2415-11-23Nucci C., Varesi C., Martucci A., Cesareo M., Cedrone C., Mancino R. et al. Efficacy of timolol 0.1% gel and a prostaglandin analog in an unfixed combination compared to the corresponding fixed combinations. Eur J Ophthalmol. 2013; 23(5):683-689. doi:10.5301/ejo.5000292Nucci C., Varesi C., Martucci A., Cesareo M., Cedrone C., Mancino R. et al. Efficacy of timolol 0.1% gel and a prostaglandin analog in an unfixed combination compared to the corresponding fixed combinations. Eur J Ophthalmol. 2013; 23(5):683-689. doi:10.5301/ejo.5000292Ozyol E., Ozyol P. The efficacy of a latanoprost/timolol fixed combi- nation versus latanoprost and timolol gel-forming solution unfixed combination on daytime intraocular pressure. J Glaucoma. 2016; 25(2):135-139. doi:10.1097/IJG.0000000000000170Ozyol E., Ozyol P. The efficacy of a latanoprost/timolol fixed combi- nation versus latanoprost and timolol gel-forming solution unfixed combination on daytime intraocular pressure. J Glaucoma. 2016; 25(2):135-139. doi:10.1097/IJG.0000000000000170Inoue K., Okayama R., Higa R., Sawada H., Wakakura M., Tomita G. Ocular hypotensive effects and safety over 3 months of switching from an unfixed combination to latanoprost 0.005%/timolol maleate 0.5% fixed combination. J Ocul Pharmacol Ther. 2011; 27(6):581-587. doi:10.1089/jop.2011.0057Inoue K., Okayama R., Higa R., Sawada H., Wakakura M., Tomita G. Ocular hypotensive effects and safety over 3 months of switching from an unfixed combination to latanoprost 0.005%/timolol maleate 0.5% fixed combination. J Ocul Pharmacol Ther. 2011; 27(6):581-587. doi:10.1089/jop.2011.0057Cheng J.W., Cheng S.W., Gao L.D., Lu G.C., Wei R.L. Intraocular pres- sure-lowering effects of commonly used fixed-combination drugs with timolol: a systematic review and meta-analysis. PLoS One. 2012; 7(9):e45079. doi:10.1371/journal.pone.0045079Cheng J.W., Cheng S.W., Gao L.D., Lu G.C., Wei R.L. Intraocular pres- sure-lowering effects of commonly used fixed-combination drugs with timolol: a systematic review and meta-analysis. PLoS One. 2012; 7(9):e45079. doi:10.1371/journal.pone.0045079Lou H., Wang H., Zong Y., Cheng J.W., Wei R.L. Efficacy and tolerability of prostaglandin-timolol fixed combinations: an updated systematic review and meta-analysis. Curr Med Res Opin. 2015; 31(6):1139-1147. doi:10.1185/03007995.2015.1039504Lou H., Wang H., Zong Y., Cheng J.W., Wei R.L. Efficacy and tolerability of prostaglandin-timolol fixed combinations: an updated systematic review and meta-analysis. Curr Med Res Opin. 2015; 31(6):1139-1147. doi:10.1185/03007995.2015.1039504Guven Yilmaz S., Degirmenci C., Karakoyun Y.E., Yusifov E., Ates H. The efficacy and safety of bimatoprost/timolol maleate, latanoprost/timolol maleate, and travoprost/timolol maleate fixed combinations on 24-h IOP. Int Ophthalmol. 2018; 38(4):1425-1431. doi:10.1007/s10792-017-0601-8Guven Yilmaz S., Degirmenci C., Karakoyun Y.E., Yusifov E., Ates H. The efficacy and safety of bimatoprost/timolol maleate, latanoprost/timolol maleate, and travoprost/timolol maleate fixed combinations on 24-h IOP. Int Ophthalmol. 2018; 38(4):1425-1431. doi:10.1007/s10792-017-0601-8Parrish R.K., Palmberg P., Sheu W.P., Group X.L.T.S. A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator mul- ticenter study. Am J Ophthalmol. 2003; 135(5):688-703. doi:10.1016/s0002-9394(03)00098-9Parrish R.K., Palmberg P., Sheu W.P., Group X.L.T.S. A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator mul- ticenter study. Am J Ophthalmol. 2003; 135(5):688-703. doi:10.1016/s0002-9394(03)00098-9Rigollet J.P., Ondategui J.A., Pasto A., Lop L. Randomized trial compa- ring three fixed combinations of prostaglandins/prostamide with timolol maleate. Clin Ophthalmol. 2011; 5:187-191. doi:10.2147/OPTH.S16666Rigollet J.P., Ondategui J.A., Pasto A., Lop L. Randomized trial compa- ring three fixed combinations of prostaglandins/prostamide with timolol maleate. Clin Ophthalmol. 2011; 5:187-191. doi:10.2147/OPTH.S16666Holmstrom S., Buchholz P., Walt J., Wickstrom J., Aagren M. Ana- lytic review of bimatoprost, latanoprost and travoprost in primary open angle glaucoma. Curr Med Res Opin. 2005; 21(11):1875-1883. doi:10.1185/030079905X65600Holmstrom S., Buchholz P., Walt J., Wickstrom J., Aagren M. Ana- lytic review of bimatoprost, latanoprost and travoprost in primary open angle glaucoma. Curr Med Res Opin. 2005; 21(11):1875-1883. doi:10.1185/030079905X65600Centofanti M., Oddone F., Vetrugno M., Manni G., Fogagnolo P., Tanga L. et al. Efficacy of the fixed combinations of bimatoprost or latanoprost plus timolol in patients uncontrolled with prostaglandin monotherapy: a multicenter, randomized, investigator-masked, clinical study. Eur J Ophthalmol. 2009; 19(1):66-71. doi:10.1177/112067210901900110Centofanti M., Oddone F., Vetrugno M., Manni G., Fogagnolo P., Tanga L. et al. Efficacy of the fixed combinations of bimatoprost or latanoprost plus timolol in patients uncontrolled with prostaglandin monotherapy: a multicenter, randomized, investigator-masked, clinical study. Eur J Ophthalmol. 2009; 19(1):66-71. doi:10.1177/112067210901900110Martinez A., Sanchez M. A comparison of the safety and intra- ocular pressure lowering of bimatoprost/timolol fixed combina- tion versus latanoprost/timolol fixed combination in patients with open-angle glaucoma. Curr Med Res Opin. 2007; 23(5):1025-1032. doi:10.1185/030079907x182149Martinez A., Sanchez M. A comparison of the safety and intra- ocular pressure lowering of bimatoprost/timolol fixed combina- tion versus latanoprost/timolol fixed combination in patients with open-angle glaucoma. Curr Med Res Opin. 2007; 23(5):1025-1032. doi:10.1185/030079907x182149Martinez A., Sanchez M. Bimatoprost/timolol fixed combination vs latanoprost/timolol fixed combination in open-angle glaucoma patients. Eye (Lond). 2009; 23(4):810-818. doi:10.1038/eye.2008.148Martinez A., Sanchez M. Bimatoprost/timolol fixed combination vs latanoprost/timolol fixed combination in open-angle glaucoma patients. Eye (Lond). 2009; 23(4):810-818. doi:10.1038/eye.2008.148Denis P., Lafuma A., Jeanbat V., Laurendeau C., Berdeaux G. Intraocular pressure control with latanoprost/timolol and travoprost/timo- lol fixed combinations: a retrospective, multicentre, cross-sectional study. Clin Drug Invest. 2008; 28(12):767-776. doi:10.2165/0044011-200828120-00004Denis P., Lafuma A., Jeanbat V., Laurendeau C., Berdeaux G. Intraocular pressure control with latanoprost/timolol and travoprost/timo- lol fixed combinations: a retrospective, multicentre, cross-sectional study. Clin Drug Invest. 2008; 28(12):767-776. doi:10.2165/0044011-200828120-00004Shoji T., Sato H., Mizukawa A., Hirota N., Enoki T., Kojima T. et al. Hypotensive effect of latanoprost/timolol versus travoprost/timolol fixed combinations in NTG patients: a randomized, multicenter, cross- over clinical trial. Invest Ophthalmol Vis Sci. 2013; 54(9):6242-6247. doi:10.1167/iovs.13-11942.Shoji T., Sato H., Mizukawa A., Hirota N., Enoki T., Kojima T. et al. Hypotensive effect of latanoprost/timolol versus travoprost/timolol fixed combinations in NTG patients: a randomized, multicenter, cross- over clinical trial. Invest Ophthalmol Vis Sci. 2013; 54(9):6242-6247. doi:10.1167/iovs.13-11942.Fuwa M., Ueda K., Akaishi T., Yamashita N., Kirihara T., Shimazaki A. et al. Advantages of efficacy and safety of fixed-dose tafluprost/timo- lol combination over fixed-dose latanoprost/timolol combination. PLoS One. 2016; 11(7):e0158797. doi:10.1371/journal.pone.0158797Fuwa M., Ueda K., Akaishi T., Yamashita N., Kirihara T., Shimazaki A. et al. Advantages of efficacy and safety of fixed-dose tafluprost/timo- lol combination over fixed-dose latanoprost/timolol combination. PLoS One. 2016; 11(7):e0158797. doi:10.1371/journal.pone.0158797Stewart W.C., Konstas A.G., Nelson L.A., Kruft B. Meta-analysis of 24-hour intraocular pressure studies evaluating the efficacy of glau- coma medicines. Ophthalmology. 2008; 115(7):1117-1122 e1111. doi:10.1016/j.ophtha.2007.10.004Stewart W.C., Konstas A.G., Nelson L.A., Kruft B. Meta-analysis of 24-hour intraocular pressure studies evaluating the efficacy of glau- coma medicines. Ophthalmology. 2008; 115(7):1117-1122 e1111. doi:10.1016/j.ophtha.2007.10.004Shin D.H., Feldman R.M., Sheu W.P., Fixed Combination Latano- prost/Timolol Study G. Efficacy and safety of the fixed combinations latanoprost/timolol versus dorzolamide/timolol in patients with ele- vated intraocular pressure. Ophthalmology. 2004; 111(2):276-282. doi:10.1016/j.ophtha.2003.05.019Shin D.H., Feldman R.M., Sheu W.P., Fixed Combination Latano- prost/Timolol Study G. Efficacy and safety of the fixed combinations latanoprost/timolol versus dorzolamide/timolol in patients with ele- vated intraocular pressure. Ophthalmology. 2004; 111(2):276-282. doi:10.1016/j.ophtha.2003.05.019Eren M.H., Gungel H., Altan C., Pasaoglu I.B., Sabanci S. Comparison of dorzolamide/timolol and latanoprost/timolol fixed combinations on diurnal intraocular pressure control in primary open-angle glaucoma. J Ocul Pharmacol Ther. 2012; 28(4):381-386. doi:10.1089/jop.2011.0105Eren M.H., Gungel H., Altan C., Pasaoglu I.B., Sabanci S. Comparison of dorzolamide/timolol and latanoprost/timolol fixed combinations on diurnal intraocular pressure control in primary open-angle glaucoma. J Ocul Pharmacol Ther. 2012; 28(4):381-386. doi:10.1089/jop.2011.0105Cvenkel B., Stewart J.A., Nelson L.A., Stewart W.C. Dorzolamide/timo- lol fixed combination versus latanoprost/timolol fixed combination in patients with primary open-angle glaucoma or ocular hypertension. Curr Eye Res. 2008; 33(2):163-168. doi:10.1080/02713680701832480Cvenkel B., Stewart J.A., Nelson L.A., Stewart W.C. Dorzolamide/timo- lol fixed combination versus latanoprost/timolol fixed combination in patients with primary open-angle glaucoma or ocular hypertension. Curr Eye Res. 2008; 33(2):163-168. doi:10.1080/02713680701832480He M., Wang W., Huang W. Efficacy and tolerability of the fixed com- binations latanoprost/timolol versus dorzolamide/timolol in patients with elevated intraocular pressure: a meta-analysis of randomized controlled trials. PLoS One. 2013; 8(12):e83606. doi:10.1371/jour-nal.pone.0083606He M., Wang W., Huang W. Efficacy and tolerability of the fixed com- binations latanoprost/timolol versus dorzolamide/timolol in patients with elevated intraocular pressure: a meta-analysis of randomized controlled trials. PLoS One. 2013; 8(12):e83606. doi:10.1371/jour-nal.pone.0083606Inoue K., Soeda S., Tomita G. Comparison of latanoprost/timolol with carbonic anhydrase inhibitor and dorzolamide/timolol with prosta- glandin analog in the treatment of glaucoma. J Ophthalmol. 2014; 2014:975429. doi:10.1155/2014/975429Inoue K., Soeda S., Tomita G. Comparison of latanoprost/timolol with carbonic anhydrase inhibitor and dorzolamide/timolol with prosta- glandin analog in the treatment of glaucoma. J Ophthalmol. 2014; 2014:975429. doi:10.1155/2014/975429

The authors declare that there are no conflicts of interest present.